Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-2330b + sevelamer
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
DS-2330b + sevelamer is an oral combination therapy investigated for the management of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing hemodialysis. DS-2330b is a small molecule inhibitor of the NaPi-IIb transporter, designed to reduce intestinal phosphate absorption. Sevelamer is a phosphate-binding polymer that limits phosphate absorption in the gastrointestinal tract. The combination was studied for potential additive or synergistic reduction of serum phosphate. In phase 1b studies, the combination was found to be safe and well tolerated, but did not demonstrate clinically meaningful efficacy in lowering serum phosphate in hemodialysis patients[1][2][3].
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)
Beyond the preview
Go deeper on DS-2330b + sevelamer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-2330b + sevelamer.